Mergers and innovation in the pharmaceutical industry.

Conflicting trends confound the pharmaceutical industry. The productivity of pharmaceutical innovation has declined in recent years. At the same time, the cohort of large companies who are the leading engines of pharmaceutical R&D has become increasingly concentrated. The concurrent presence of these trends is not sufficient to determine causation. In response to lagging innovation prospects, some companies have sought refuge in mergers and acquisitions to disguise their dwindling prospects or gain R&D synergies. On the other hand, the increased concentration brought on by recent mergers may have contributed to the declining rate of innovation. In this paper, we consider the second of these causal relationships: the likely impact of the recent merger wave among the largest pharmaceutical companies on the rate of innovation. In other words, have recent mergers, which may have been taken in response to lagging innovation, represented a self-defeating strategy that only made industry outcomes worse?

[1]  William S. Comanor,et al.  Research and Competitive Product Differentiation in the Pharmaceutical Industry in the United States , 1964 .

[2]  Jacques Mairesse,et al.  Measuring the Returns to R&D , 2009, SSRN Electronic Journal.

[3]  Henry G. Grabowski,et al.  A New Look at the Returns and Risks to Pharmaceutical R&D , 1990 .

[4]  William S. Comanor.  Pharmaceutical Innovation: The Economics of Research and Development in the Pharmaceutical Industry , 2007 .

[5]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[6]  Frederic M. Scherer,et al.  Industry structure, strategy, and public policy , 1996 .

[7]  J. DiMasi,et al.  The economics of follow-on drug research and development , 2012, PharmacoEconomics.

[8]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[9]  F. Scherer,et al.  Patent Statistics as a Measure of Technical Change , 1969, Journal of Political Economy.

[10]  John L. LaMattina,et al.  The impact of mergers on pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[11]  F. Scherer.  Chapter 12 – Pharmaceutical Innovation , 2010 .

[12]  I. Cockburn,et al.  Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. , 2001, Journal of health economics.

[13]  F. Lichtenberg.  Pharmaceutical Knowledge-Capital Accumulation and Longevity , 2005 .

[14]  Edwin Mansfield,et al.  Social and Private Rates of Return from Industrial Innovations , 1977 .

[15]  R. Nelson.  Uncertainty, Learning, and the Economics of Parallel Research and Development Efforts , 1961 .

[16]  Frederic M. Scherer,et al.  Time-cost tradeoffs in uncertain empirical research projects , 1966 .

[17]  William Fellner,et al.  The Influence of Market Structure on Technological Progress , 1951 .

[18]  F. Lichtenberg,et al.  Economic Growth , 1957, The Journal of Economic History.

[19]  Jens Naumann.  The economics of research and development , 1965 .

[20]  J. DiMasi,et al.  Returns on Research and Development for 1990s New Drug Introductions , 2012, PharmacoEconomics.

[21]  C. Hitch,et al.  The Economics of Defense in the Nuclear Age. By Charles J. Hitch and Roland N. McKean. (Cambridge: Harvard University Press, 1960. Pp. xiii, 422. $9.50.) , 1961 .

[22]  Richard E. Stockwell,et al.  The weapons acquisition process: An economic analysis , 1963 .

[23]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[24]  W. S. Comanor,et al.  Strategic Pricing of New Pharmaceuticals , 1998, Review of Economics and Statistics.

[25]  Dan Primack.  Why you should blame Wall Street for pharma's startup problem. , 2011, Fortune.

[26]  William J. Abernathy,et al.  Parallel Strategies in Development Projects , 1969 .

[27]  Rebecca Henderson,et al.  Managing innovation in the information age , 1994 .